| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
5-HT1A Receptor D3 Receptor D2 Receptor
Didesmethyl cariprazine targets dopamine D3 and D2 receptors, and the 5-HT1A receptor. As a metabolite of cariprazine, it is a partial agonist at dopamine D3/D2 receptors. By modulating dopaminergic and serotonergic signaling, it contributes to the antipsychotic effects of cariprazine. Its long half-life makes it a major active moiety in vivo. |
|---|---|
| ln Vitro |
In vitro, Didesmethyl cariprazine is used as a reference standard and to study the activity of cariprazine metabolites. Its activity is similar to that of cariprazine, with affinity for D3, D2, and 5-HT1A receptors. Standard in vitro assays include receptor binding studies using radiolabeled ligands and functional assays measuring cAMP accumulation or [35S]GTPγS binding to assess receptor activity.
|
| ln Vivo |
In vivo, Didesmethyl cariprazine is the major circulating active metabolite of cariprazine, with a longer half-life of 1-3 weeks. It contributes to the antipsychotic effects of cariprazine in the treatment of schizophrenia, bipolar mania, and depression. Its long half-life is important for the pharmacokinetic profile of the parent drug.
|
| Enzyme Assay |
For non-cell-based receptor binding assays, Didesmethyl cariprazine can be evaluated using membrane preparations from cells expressing human dopamine D2, D3, or 5-HT1A receptors. Radioligand binding displacement experiments are performed using suitable radiolabeled ligands such as [3H]-spiperone for D2-like receptors or [3H]-8-OH-DPAT for 5-HT1A. Membrane homogenates are incubated with increasing concentrations of the test compound and a fixed concentration of the radioligand. Bound radioligand is separated from free by rapid filtration. Non-specific binding is determined in the presence of excess unlabeled ligand. Ki values are calculated from displacement curves.
|
| Cell Assay |
For in vitro cellular assays, cells expressing dopamine D2, D3, or 5-HT1A receptors are cultured in appropriate media. For functional assays, the appropriate signaling readout is measured. Cells are treated with various concentrations of Didesmethyl cariprazine, and the signaling response is measured. EC50 or IC50 values are calculated from dose-response curves.
|
| Animal Protocol |
For in vivo animal studies, Didesmethyl cariprazine is not typically administered as a separate compound. Its levels are measured in pharmacokinetic studies following administration of cariprazine. Blood or tissue samples are collected and analyzed by LC-MS/MS to quantify the metabolite.
|
| ADME/Pharmacokinetics |
Didesmethyl cariprazine has a molecular formula and weight as described in the literature. It is a metabolite of cariprazine. The compound should be stored at -20°C for long-term stability. It is for research use only and is not intended for human consumption.
|
| Toxicity/Toxicokinetics |
The toxicity profile of Didesmethyl cariprazine is assessed as part of the safety evaluation of cariprazine. As an active metabolite, it contributes to the pharmacological effects and potential side effects of the parent drug. The compound is for research use only and is not intended for human consumption.
|
| References | |
| Additional Infomation |
Didesmethyl cariprazine (CAS 839712-25-3) is an active metabolite of cariprazine. It is the major circulating active moiety and has a longer half-life of 1-3 weeks. Cariprazine is an antipsychotic agent that exhibits high affinity for D3 and D2 receptors, and moderate affinity for 5-HT1A. Didesmethyl cariprazine is used in neuroscience research. It is available for research purposes only.
|
| Molecular Formula |
C19H28CL2N4O
|
|---|---|
| Molecular Weight |
399.357822418213
|
| Exact Mass |
398.164
|
| CAS # |
839712-25-3
|
| PubChem CID |
11200383
|
| Appearance |
Off-white to light yellow solid powder
|
| LogP |
3.7
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
26
|
| Complexity |
451
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
ClC1C(Cl)=CC=CC=1N1CCN(CC[C@@H]2CC[C@@H](NC(=O)N)CC2)CC1
|
| InChi Key |
UMTWXZNVNBBFLC-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C19H28Cl2N4O/c20-16-2-1-3-17(18(16)21)25-12-10-24(11-13-25)9-8-14-4-6-15(7-5-14)23-19(22)26/h1-3,14-15H,4-13H2,(H3,22,23,26)
|
| Chemical Name |
[4-[2-[4-(2,3-dichlorophenyl)piperazin-1-yl]ethyl]cyclohexyl]urea
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 11.36 mg/mL (28.45 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5040 mL | 12.5200 mL | 25.0401 mL | |
| 5 mM | 0.5008 mL | 2.5040 mL | 5.0080 mL | |
| 10 mM | 0.2504 mL | 1.2520 mL | 2.5040 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
